Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

MAB1965

Sigma-Aldrich

Anti-Integrin β1 Antibody, a.a. 82-87, clone JB1A (a.k.a. J10)

ascites fluid, clone JB1A (J10), Chemicon®

Sinónimos:

CD29

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

100
300

antibody form

ascites fluid

antibody product type

primary antibodies

clone

JB1A (J10), monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

flow cytometry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... ITGB1(3688)

General description

The primary function of the integrin family is to mediate cell-cell and cell-matrix adhesion interaction. CD29 is ubiquitous, with broad tissue distribution, but is not expressed on erythrocytes and is expressed only weakly on granulocytes. Integrins play an important role in cell adhesion and migration, and their normal function is critical in the induction and maintenance of cell differentiation. Loss or downregulation of CD29 has been proposed to be one of the general pathways through which carcinoma cells may acquire a more invasive and differentiated phenotype. Furthermore, loss or downregulation of integrin occurs relatively frequently in poorly differentiated colorectal and breast carcinomas as determined by immunohistochemistry.

Specificity

Reacts with the human integrin beta 1. Note: integrin beta 1 is expressed in all tissues/cell types except erythrocytes. The epitope recognized by JB1a was recently mapped to residues 82-87 of the mature beta 1 integrin chain. In this study Mn++ was found to inhibit binding of JB1a both to mature beta 1 integrin and to a synthetic peptide corresponding to residues 82-87{Ni, 1998}.

Immunogen

Epitope: a.a. 82-87
Purified beta 1 integrin and Jurkat cells

Application

Inhibition of Jurkat binding to collagen and fibronectin:
1:100 Note: epitope is trypsin sensitive; cells should be prepared with PBS + EDTA (2mM) or other non-enzymatic methods. Blocking will not occur with trypsinized cells with JB1A.

Immunoprecipitation: 1:250-500

Western blotting (reducing, 115 kDa; non-reducing, 130 kDa): 1:1000-2000

Note: binding of antibody may be inhibited by magnesium ion concentrations exceeding 0.5mM.

Immunocytochemistry/Immunohistochemistry: JB1A can be used on unfixed cells in flow cytometry and culture {Akimov, 2001; Blood 98(5):1567-1576}. Often times fixing with 2-3% PFA for 5 minutes after primary antibody incubation will assist in obtain strong signals since it fixes the primary antibodies to the tissues.

FACS: JB1A has been primarily used against live cells at 1:200-1:500 followed by goat anti-mouse conjugated secondaries

Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Research Sub Category
Integrins
This Anti-Integrin β1 Antibody, a.a. 82-87, clone JB1A (a.k.a. J10) is validated for use in FC, IH, IP, FUNC, WB for the detection of Integrin β1.

Target description

88 kDa

Physical form

Ascites fluid containing no preservatives.
Unpurified

Storage and Stability

Maintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
Human lung, liver, and skeletal muscle tissues

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Optional

Storage Class

10 - Combustible liquids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Tomoya Isaji et al.
The Journal of biological chemistry, 284(18), 12207-12216 (2009-03-06)
N-Glycosylation of integrin alpha5beta1 plays a crucial role in cell spreading, cell migration, ligand binding, and dimer formation, but the detailed mechanisms by which N-glycosylation mediates these functions remain unclear. In a previous study, we showed that three potential N-glycosylation
Juliette Ezpeleta et al.
Scientific reports, 7(1), 7671-7671 (2017-08-11)
Although cellular prion protein PrPC is well known for its implication in Transmissible Spongiform Encephalopathies, its functions remain elusive. Combining in vitro and in vivo approaches, we here show that PrPC displays the intrinsic capacity to protect neuronal cells from
Li-Yan Li et al.
Oncotarget, 6(18), 15940-15952 (2015-04-25)
The paucity of new drugs for the treatment of esophageal squamous cell carcinoma (ESCC) limits the treatment options. This study characterized the therapeutic efficacy and action mechanism of a novel natural macrolide compound F806 in human ESCC xenograft models and
Claudia S Priglinger et al.
PloS one, 8(7), e70011-e70011 (2013-08-08)
Proliferative vitreoretinopathy (PVR) is a blinding disease frequently occurring after retinal detachment surgery. Adhesion, migration and matrix remodeling of dedifferentiated retinal pigment epithelial (RPE) cells characterize the onset of the disease. Treatment options are still restrained and identification of factors
Elisa H F Jandrey et al.
NPJ breast cancer, 5, 11-11 (2019-04-10)
The risk of developing metastatic disease in breast cancer patients is traditionally predictable based on the number of positive axillary lymph nodes, complemented with additional clinicopathological factors. However, since lymph node-negative patients have a 20-30% probability of developing metastatic disease

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico